January 2008 Volume 26 Number 1, pp 1 - 136
Visit Nature Biotechnology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0dXt0Eu
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0aAP0Es
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0BRQi0EQ
Bioentrepreneur: an online resource for budding business in the life sciences.
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0BkE0Es
=====================================================================
Are you looking for a partner?
Let us help you select suitable interaction partners by using the Attana A100 C-Fast system: label-free, molecular interaction analysis in real time.
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0BP8f0Eu
=====================================================================
=====================================================================
SciBX: Science-Business eXchange
From the makers of BioCentury and Nature. A groundbreaking publication that will transform your ability to efficiently identify and evaluate new developments in science and technology that have commercial and investment potential within the biotechnology and pharmaceutical arena.
Visit http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0BktW0E7 for details on the special SciBX Charter Subscriber Offer.
=====================================================================
=====================================================================
Nature Biotechnology and Nature Reviews Drug Discovery present
Focus on Antivirals
This print and web focus comprehensively summarizes the science and business of antiviral drug R&D, highlighting innovative approaches and lessons learned from decades of antiviral drug development, as well as identifying key issues for future antiviral drug discovery and potential solutions.
To access this special focus visit: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bh2H0Ei
Generously supported by: Gilead and Pfizer
=====================================================================
----------------------
EDITORIAL
----------------------
The regulator disapproves p1
Pressure is mounting on the US Food and Drug Administration (FDA) to explain its decision to ignore an advisory committee's positive recommendation for the cancer vaccine Provenge.
doi:10.1038/nbt0108-1
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2F0Ej
----------------------
NEWS
----------------------
Merck's HIV vaccine flop brings vectors under closer scrutiny pp3 - 4
Heidi Ledford
doi:10.1038/nbt0108-3
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2G0Ek
Fractured European market undermines biosimilar launches pp5 - 6
Nuala Moran
doi:10.1038/nbt0108-5
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2H0El
Government report critical of FDA blasted as misleading p7
Jeffrey L. Fox
doi:10.1038/nbt0108-7
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2I0Em
Cellulosic ethanol booms despite unproven business models pp8 - 9
Emily Waltz
doi:10.1038/nbt0108-8
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2J0En
IN BRIEF
News in brief pp11 - 12
doi:10.1038/nbt0108-11
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2K0Eo
PROFILE
Greg Simon p13
Charismatic FasterCures president Greg Simon is on a mission to galvanize US biomedical research[mdash]and he's starting by changing attitudes to the sharing of donated patient materials.
Crispin Littlehales
doi:10.1038/nbt0108-13
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2L0Ep
DATA PAGE
Wage power in the life sciences p14
Stacy Lawrence
doi:10.1038/nbt0108-14
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2M0Eq
----------------------
NEWS FEATURES
----------------------
Biotech as Bush bows out pp15 - 18
Follow-on biologics, changes to the patent system, new rules from the FDA and the prospect of a new party in the White House dominate the policy outlook for biotechs. Aaron Lorenzo reports.
Aaron Lorenzo
doi:10.1038/nbt0108-15
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2N0Er
Shareholders flex their muscles pp19 - 21
Investor activism hits the biotech industry with mixed results. Karl Thiel investigates.
Karl Thiel
doi:10.1038/nbt0108-19
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2O0Es
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Giving patients a say: how to work with patient advocacy groups pp23 - 26
Working with patient advocacy groups poses many challenges to entrepreneurs, but the benefits can be substantial. Here, we examine the relationship between biotech PTC Therapeutics and Parent Project Muscular Dystrophy to highlight some key factors for success in such partnerships.
Anne-Laure Winkler and David Finegold
doi:10.1038/bioe.2007.6
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2P0Et
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
We speak for small biotech p27
Stephen A Sherwin
doi:10.1038/nbt0108-27a
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2Q0Eu
We speak for small biotech pp27 - 28
Johan Vanhemelrijck
doi:10.1038/nbt0108-27b
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2R0Ev
Where did the scientific method go? pp28 - 29
Michela Noseda and Gary R McLean
doi:10.1038/nbt0108-28
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2S0Ew
Response to Where did the scientific method go? p29
doi:10.1038/nbt0108-29a
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2T0Ex
Ethics of research on human biological materials pp29 - 30
Laurence Lwoff
doi:10.1038/nbt0108-29b
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2U0Ey
COMMENTARY
Privatizing biomedical research[mdash]a 'third way' pp31 - 36
Ron A Bouchard and Trudo Lemmens
doi:10.1038/nbt0108-31
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2V0Ez
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2W0E1
----------------------
FEATURE
----------------------
Chinese health biotech and the billion-patient market pp37 - 53
Chinese government support and 'sea turtles' are spurring the sector, but investors lack exits.
Sarah E Frew et al.
doi:10.1038/nbt0108-37
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2X0E2
PATENTS
Reach-through claims for drug target patents: Rx for pharmaceutical policy pp55 - 56
Recognizing the value of the discovery and validation of new pharmaceutical targets would be a major step forward for pharmaceutical policy.
Robert A Bohrer
doi:10.1038/nbt0108-55
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2Y0E3
Recent patent applications in antibodies p57
doi:10.1038/nbt0108-57
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2Z0E4
----------------------
NEWS AND VIEWS
----------------------
Simpler and safer cell reprogramming pp59 - 60
Induced pluripotent stem cells have been generated from mouse and human adult fibroblasts without the tumor-causing gene c-Myc.
Martin F Pera and Kouichi Hasegawa
doi:10.1038/nbt0108-59
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2a0EC
Illuminating the switch in influenza viruses pp60 - 62
Integrating data from glycan microarrays and X-ray structures sheds light on human adaptation of influenza viruses.
Carole A Bewley
doi:10.1038/nbt0108-60
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2b0ED
Humanizing mouse thrombi pp62 - 63
A new mouse model with humanized blood vessels will facilitate testing of antiplatelet therapies.
Ingo Ahrens and Karlheinz Peter
doi:10.1038/nbt0108-62
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2c0EE
Primate therapeutic cloning in practice pp64 - 65
The derivation of primate embryonic stem cells by nuclear transfer marks an advance toward human therapeutic cloning.
John Gurdon
doi:10.1038/nbt0108-64
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2d0EF
Genome resequencing and genetic variation pp65 - 66
Technologies for selecting segments of large genomes for resequencing will reveal biologically important sequence variation.
Michael Stratton
doi:10.1038/nbt0108-65
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2e0EG
Research highlights p67
doi:10.1038/nbt0108-67
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2f0EH
----------------------
COMPUTATIONAL BIOLOGY
----------------------
COMMENTARY
Protein-protein interaction networks and biology[mdash]what's the connection? pp69 - 72
Analysis of protein-protein interaction networks is an increasingly popular means to infer biological insight, but is close enough attention being paid to data handling protocols and the degree of bias in the data?
Luke Hakes, John W Pinney, David L Robertson and Simon C Lovell
doi:10.1038/nbt0108-69
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2g0EI
----------------------
RESEARCH
----------------------
PERSPECTIVE
Allergenicity assessment of genetically modified crops[mdash]what makes sense? pp73 - 81
Richard E Goodman et al.
doi:10.1038/nbt1343
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2h0EJ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2i0EK
ARTICLES
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags pp83 - 90
Ximei Qian et al.
doi:10.1038/nbt1377
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2j0EL
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2k0EM
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo pp91 - 100
Erik Henke et al.
doi:10.1038/nbt1366
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2l0EN
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2m0EO
LETTERS
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts pp101 - 106
Masato Nakagawa et al.
doi:10.1038/nbt1374
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2n0EP
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2o0EQ
Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin pp107 - 113
Aarthi Chandrasekaran et al.
doi:10.1038/nbt1375
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2p0ER
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2q0ES
Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies pp114 - 119
Jianchun Chen et al.
doi:10.1038/nbt1373
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2r0ET
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2s0EU
Microscale culture of human liver cells for drug development pp120 - 126
Salman R Khetani and Sangeeta N Bhatia
doi:10.1038/nbt1361
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2t0EV
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2u0EW
A quantitative analysis of kinase inhibitor selectivity pp127 - 132
Mazen W Karaman et al.
doi:10.1038/nbt1358
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2v0EX
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2w0EY
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Executive compensation at private biotech companies: a competitive environment pp133 - 134
It was another good year for life science industry executives as venture capital investment continued to rise. How does your company compare?
Bruce Rychlik and Mike DiPierro
doi:10.1038/nbt0108-133
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2x0EZ
PEOPLE
People p136
doi:10.1038/nbt0108-136
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Bk2y0Ea
=====================================================================
Nature Methods' Method of the Year 2007.
Technological developments often drive scientific progress, so let's celebrate methods development for its own sake! Nature Methods' editors have selected the methodological development that most impressed them in 2007 because it came into its own and started impacting a wide variety of research areas. Visit the Nature Methods website at http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0K7N0EK to discover the champion, read the story of its development and hear from expert users about its applications. And since the decision was tough, there is also a selection of 'Methods to Watch' for the years to come!
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/eiZ50Xztnp0HjC0Zzu0EL
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
